Pediatrix Medical Group, Inc. (MD)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Whoever buys today is betting that the reimbursement gains carry the results until volumes turn — and that the Medicaid cuts depress rates more slowly than management can renegotiate. Whoever waits will find two simple markers in the coming quarterly reports: do patient volumes swing back to growth, and does the payor mix stay stable? The next report is scheduled for August 4, 2026. The decision is yours.
symbol.quality_note
Pediatrix Medical Group surfaced in our Reddit hype scanner — under the name "Mednax", which has not existed since 2022 (2 mentions in 24 hours, as of July 15, 2026). We nailed down the identity in the SEC register and read the annual reports (10-K) for 2024 and 2025 plus the quarterly report (10-Q) as of March 31, 2026: a genuine profit turnaround to $165.4 million and a share price up about 81 percent in twelve months — but 53 percent of gross billings go to government programs that pay "substantially less", a law signed on July 4, 2025 cuts Medicaid, and patient volumes just shrank. Not investment advice — just the second opinion before the ward round.
Read the analysis
Stock Watch
This analysis is as of July 16, 2026. Stock Watch will tell you what's changed at MD since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 15 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 26.50 $ — 94% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Uses AIPediatrix setzt KI laut Geschäftsbericht (10-K für 2025) operativ ein — die eigenen Informationssysteme für Tagesbetrieb, klinische Initiativen und Geschäftsanalysen nutzen zunehmend KI, insbesondere zur Unterstützung der klinischen Dokumentation; das elektronische Patientenakten-System enthält KI-Werkzeuge für die Arzt-Dokumentation. KI-Produkte sind keine Umsatzquelle, und ein konkretes KI-Risiko für das Geschäftsmodell (Arztleistungen in Neugeborenen-Intensivstationen) benennen die Filings nicht — nur die generischen Einsatz- und Wettbewerbsrisiken der eigenen Nutzung.
View the full file — quotes, sources, reviewed filings
„Some of our information systems that support our day-to-day operations, ongoing clinical initiatives and business analyses increasingly utilize AI, including to assist with clinical documentation. AI technologies are highly complex and rapidly evolving, and their use presents risks, challenges and the potential for unintended consequences, including errors, bias, system failures, or limitations in performance, which could affect their adoption or effectiveness and, in turn, our operations and business."
Einige unserer Informationssysteme, die unseren Tagesbetrieb, laufende klinische Initiativen und Geschäftsanalysen unterstützen, nutzen zunehmend KI — unter anderem zur Unterstützung der klinischen Dokumentation. KI-Technologien sind hochkomplex und entwickeln sich rasant; ihr Einsatz birgt Risiken, Herausforderungen und das Potenzial unbeabsichtigter Folgen, darunter Fehler, Verzerrungen, Systemausfälle oder Leistungsgrenzen, die ihre Einführung oder Wirksamkeit und damit unseren Betrieb und unser Geschäft beeinträchtigen könnten.
„This product line provides additional benefits to our ambulatory practices, including clinical decision trees to assist physicians with the selection of compliant billing codes, medication management (including electronic prescription of controlled substance and prescription drug monitoring programs), promotion of consistent documentation, patient engagement tools, virtual visits and telemedicine tools, Artificial intelligence tools for streamlined clinician documentation, a new referral management template, and data for research and education."
Diese Produktlinie bietet unseren ambulanten Praxen zusätzliche Vorteile, darunter klinische Entscheidungsbäume zur Unterstützung der Ärzte bei der Auswahl regelkonformer Abrechnungscodes, Medikamentenmanagement (einschließlich elektronischer Verschreibung kontrollierter Substanzen und Programmen zur Überwachung verschreibungspflichtiger Arzneimittel), Förderung einer einheitlichen Dokumentation, Werkzeuge zur Patienteneinbindung, virtuelle Visiten und Telemedizin-Werkzeuge, Künstliche-Intelligenz-Werkzeuge für eine gestraffte Dokumentation der Kliniker, eine neue Vorlage für das Überweisungsmanagement sowie Daten für Forschung und Lehre.
„At the same time, our ability to remain competitive may depend in part on our ability to effectively develop, implement and utilize AI technologies. If we are unable to keep pace with technological developments or the adoption of AI by competitors, or if competitors are able to achieve greater operational efficiencies, cost savings, or service enhancements through their use of AI, our competitive position, operating results, or growth prospects could be adversely affected."
Zugleich kann unsere Wettbewerbsfähigkeit teilweise davon abhängen, ob wir KI-Technologien wirksam entwickeln, einführen und nutzen können. Sollten wir mit der technologischen Entwicklung oder der KI-Einführung durch Wettbewerber nicht Schritt halten, oder sollten Wettbewerber durch ihren KI-Einsatz größere operative Effizienzgewinne, Kosteneinsparungen oder Leistungsverbesserungen erzielen können, könnten unsere Wettbewerbsposition, unser Betriebsergebnis oder unsere Wachstumsaussichten beeinträchtigt werden.
Filings Reviewed: 10-Q 2026-05-05 · 10-Q 2025-11-03 · 10-Q 2025-08-05 · 10-Q 2025-05-06 · 10-K 2026-02-19 · 10-K 2025-02-20
Rated on July 16, 2026 · How the Rating Is Built
Analysts & Price Target
The price target sits 7.5% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.28 | 2.17 – 2.37 | 1,939 | 11.6% | 7 |
| 12/31/2027 | 2.36 | 2.12 – 2.59 | 1,988 | 3.7% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.54 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.35 | – | 502 | 1.20 | 6.10 | 133 | 130 |
| 2025: Q1 | 0.24 | 398.70 | 458 | -7.40 | 4.50 | -118 | -121 |
| 2025: Q2 | 0.45 | – | 469 | -7.00 | 8.40 | 137 | 133 |
| 2025: Q3 | 0.84 | 264.20 | 493 | -3.60 | 14.50 | 137 | 132 |
| 2025: Q4 | 0.40 | 12.40 | 494 | -1.70 | 6.80 | 114 | 109 |
| 2026: Q1 | 0.36 | 47.30 | 476 | 3.90 | 6.20 | -130 | -136 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 3,183 | 572 | 325 | 3.47 | 444 | 2,761 | 5,339 |
| 2017 | 3,458 | 480 | 320 | 3.42 | 511 | 3,066 | 5,867 |
| 2018 | 3,647 | 446 | 269 | 2.93 | 290 | 3,088 | 5,935 |
| 2019 | 1,780 | 172 | -1,498 | -17.78 | 347 | 1,499 | 4,146 |
| 2020 | 1,734 | 98 | -796 | -9.31 | 205 | 747 | 3,348 |
| 2021 | 1,911 | 203 | 131 | 1.52 | 77 | 896 | 2,723 |
| 2022 | 1,972 | 173 | 66 | 0.79 | 167 | 892 | 2,348 |
| 2023 | 1,995 | 7 | -60 | -0.73 | 137 | 849 | 2,220 |
| 2024 | 2,013 | -69 | -99 | -1.19 | 207 | 765 | 2,153 |
| 2025 | 1,914 | 231 | 165 | 1.94 | 271 | 866 | 2,247 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
The largest neonatology network in the U.S.: 1,350 of the country's roughly 7,200 board-certified neonatologists, more than 360 staffed and managed NICUs in 32 states, long-standing hospital contracts — an asset-light business with high barriers to entry (annual report 10-K for 2025).
Adjusted EBITDA up two years in a row ($200.4 → $224.0 → $275.6 million, 2023–2025), net income of $165.4 million after two loss years, Q1 2026 up 43 percent; operating cash flow of $274.7 million against $18.5 million of capex, cash nearly covers the debt, a $250 million buyback program is running.
About 53 percent of gross billings go to government programs that per the report pay "substantially less" (only 24 percent of net revenue); the One Big Beautiful Bill Act of July 4, 2025 cuts Medicaid with a possible "material impact" per the report; the No Surprises Act categorically bans balance billing in neonatology; Texas bundles 32 percent of revenue.
The U.S. birth rate is in structural decline per the risk factors; same-unit patient volumes fell 1.6 percent in the first quarter of 2026 (maternal-fetal medicine and neonatology) — growth came entirely from reimbursement and collection factors (+4.4 percent) that cannot be repeated at will; 70.1 percent of revenue is tied up in practice salaries.
P/E around 12, price-to-free-cash-flow around 8, EV/adjusted EBITDA around 7.5 — moderate for the quality, but after an 81 percent twelve-month rally no longer a crisis price; analyst consensus (8 houses) on the buy side against three insider sales without a single purchase, fundamental grade C and a Piotroski score of 6 of 9 (data as of July 10, 2026).
Pediatrix is a successful turnaround with a chronic underlying condition: adjusted operating profit has grown for two consecutive years, the balance sheet is nearly debt-free on a net basis, and the NICU network holds a market position that cannot be copied. But more than half the bills go to government programs that pay substantially less and are being cut by law since July 4, 2025, patient volumes just shrank, and 70 cents of every revenue dollar are tied up in physician pay. After an 81 percent rally, a good part of the recovery is already paid for — insiders sold while analysts recommend buying. Not investment advice.
- MD reached our research list via the Reddit hype scanner (ApeWisdom, 2 mentions in 24 hours, as of July 15, 2026) — still listed there under the name "Mednax", retired in 2022; the identity was verified via the SEC register (CIK 0000893949, former names).
- The 15 hits in our in-house stock scanner carry the July 10, 2026 data cut-off and rotate daily; scanner metrics are computed from trailing twelve-month figures and reflect Q1 2026 effects only with a lag.
- Price and valuation figures are dated to July 10, 2026 (about $24, market value roughly $1.95 billion); analyses are evergreen, daily prices are not a buy argument.
About the Company
Pediatrix Medical Group, Inc. bietet gemeinsam mit ihren Tochtergesellschaften Versorgungsdienste für Neugeborene, Maternal-Fetal-Medizin und andere pädiatrische Subspezialitäten in den USA an.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 4,280 |
| Headquarters | Sunrise, FL |
| Address | 1301 Concord Terrace, 33323 Sunrise, United States |
| Phone | 954 384 0175 |
| Website | pediatrix.com |
| IPO Date | 19. Sep 1995 |
| ISIN | US58502B1061 |
| Stock Split | 2:1 on 12/20/2013 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mark S. Ordan | CEO & Executive Chairman | 1959 |
| Kasandra H. Rossi | Executive VP, Treasurer & CFO | 1973 |
| D. Gregory Neeb | Executive VP & Chief Operating and Strategy Officer | 1968 |
| John C. Pepia | Senior VP & Chief Accounting Officer | 1963 |
| Cheryl M. VanPatten | Senior VP & Chief Information Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.